PL383287A1 - Lipides composition for production of lipid carrier for genetic medicines and its application - Google Patents
Lipides composition for production of lipid carrier for genetic medicines and its applicationInfo
- Publication number
- PL383287A1 PL383287A1 PL383287A PL38328707A PL383287A1 PL 383287 A1 PL383287 A1 PL 383287A1 PL 383287 A PL383287 A PL 383287A PL 38328707 A PL38328707 A PL 38328707A PL 383287 A1 PL383287 A1 PL 383287A1
- Authority
- PL
- Poland
- Prior art keywords
- weight
- production
- composition
- lipides
- application
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych charakteryzuje się tym, że zawiera 38,7% wagowych fosfatydylocholiny (PC), 15,4% wagowych distearoilofosfatydyloetanoloaminowej pochodnej glikolu polietylenowego 2000 (sól amonowa) (DSPE-PEG), od 10,9 do 16,8% wagowych dioleiolofosfatydyloetanolaminy (DOPE), od 4,05 do 6,75% wagowych 3ß-N-dimetyloetanokarbamoilo cholesterolu (DC-CHOL) i od 23,4 do 30,6% wagowych soli trimetyloamoniowej 1,2 -dioleilopropanu (DOTAP), przy czym PC, DOPE i DC-CHOL stanowią zewnętrzna błonę nośnika, a DOTAP wchodzi skład rdzenia nośnika zamkniętego w jego wnętrzu.The lipid composition for the production of a lipid carrier for genetic drugs is characterized in that it comprises 38.7% by weight of phosphatidylcholine (PC), 15.4% by weight of distearoylphosphatidylethanolamine derivative of polyethylene glycol 2000 (ammonium salt) (DSPE-PEG), from 10.9 to 16.8% by weight of dioleoylphosphatidylethanolamine (DOPE), from 4.05 to 6.75% by weight of 3β-N-dimethylethanecarbamoyl cholesterol (DC-CHOL) and from 23.4 to 30.6% by weight of trimethylammonium salt of 1,2-dioleylpropane ( DOTAP), where PC, DOPE and DC-CHOL are the outer membrane of the carrier, and DOTAP is part of the core of the carrier enclosed inside it.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL383287A PL208054B1 (en) | 2007-09-06 | 2007-09-06 | Lipides composition for production of lipid carrier for genetic medicines and its application |
PCT/PL2008/000062 WO2009031911A1 (en) | 2007-09-06 | 2008-09-02 | Cationic liposome carrier for genetic drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL383287A PL208054B1 (en) | 2007-09-06 | 2007-09-06 | Lipides composition for production of lipid carrier for genetic medicines and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
PL383287A1 true PL383287A1 (en) | 2009-03-16 |
PL208054B1 PL208054B1 (en) | 2011-03-31 |
Family
ID=40325840
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL383287A PL208054B1 (en) | 2007-09-06 | 2007-09-06 | Lipides composition for production of lipid carrier for genetic medicines and its application |
Country Status (2)
Country | Link |
---|---|
PL (1) | PL208054B1 (en) |
WO (1) | WO2009031911A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013177421A2 (en) * | 2012-05-23 | 2013-11-28 | The Ohio State University | Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same |
US10253315B2 (en) * | 2012-08-30 | 2019-04-09 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Method for transfection of nucleic acids into eukaryotic cells in 3D scaffold |
PL233741B1 (en) | 2014-04-18 | 2019-11-29 | Wroclawskie Centrum Badan Eit Spolka Z Ograniczona Odpowiedzialnoscia | Lipid composition serving for the creation of the genetic medicines carrier managed by means of antibodies and its application |
PL407947A1 (en) * | 2014-04-18 | 2015-10-26 | Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością | Oriented, liposome form of the polyethyleneimine oligonucleotide, its application and method for obtaining it |
WO2017220099A1 (en) | 2016-06-24 | 2017-12-28 | Statens Serum Institut | Adjuvants with modified drainage properties |
CN110101664A (en) * | 2019-05-06 | 2019-08-09 | 西安交通大学医学院第一附属医院 | For delivering the system of nucleic acid drug and preparation method thereof with specific cleavage HPV16 type gene function |
CN111603571A (en) * | 2020-05-28 | 2020-09-01 | 中国药科大学 | Mitochondrion targeting lipid-like carrier Mito-Alisposome, compound thereof, preparation method and application |
CN114699420A (en) * | 2022-03-08 | 2022-07-05 | 南方科技大学 | Composition for treating prostate cancer and preparation method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1017365T3 (en) * | 1997-06-23 | 2004-03-29 | Alza Corp | Liposome enclosed polynucleotide composition and method |
US7390780B2 (en) * | 1999-04-23 | 2008-06-24 | Alza Corporation | Gene delivery mediated by liposome-DNA complex with cleavable peg surface modification |
JP2004535388A (en) * | 2001-04-30 | 2004-11-25 | ターゲティッド ジェネティクス コーポレイション | Lipid-containing drug delivery conjugates and methods for their production |
-
2007
- 2007-09-06 PL PL383287A patent/PL208054B1/en unknown
-
2008
- 2008-09-02 WO PCT/PL2008/000062 patent/WO2009031911A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
PL208054B1 (en) | 2011-03-31 |
WO2009031911A1 (en) | 2009-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL383287A1 (en) | Lipides composition for production of lipid carrier for genetic medicines and its application | |
Schlich et al. | Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles | |
Cullis et al. | Lipid nanoparticle systems for enabling gene therapies | |
Zheng et al. | Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm | |
Rajesh et al. | Dramatic influence of the orientation of linker between hydrophilic and hydrophobic lipid moiety in liposomal gene delivery | |
Grijalvo et al. | Cationic niosomes as non-viral vehicles for nucleic acids: Challenges and opportunities in gene delivery | |
Bajaj et al. | Design, synthesis, and in vitro gene delivery efficacies of novel cholesterol-based gemini cationic lipids and their serum compatibility: A structure− activity investigation | |
Hmingthansanga et al. | Improved topical drug delivery: Role of permeation enhancers and advanced approaches | |
Gomes-da-Silva et al. | Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges | |
Mochizuki et al. | The role of the helper lipid dioleoylphosphatidylethanolamine (DOPE) for DNA transfection cooperating with a cationic lipid bearing ethylenediamine | |
JP2014529328A5 (en) | ||
Pedro et al. | Ionic liquids in drug delivery | |
MX2019011004A (en) | Compounds and compositions for intracellular delivery of therapeutic agents. | |
Koynova et al. | Hydrophobic moiety of cationic lipids strongly modulates their transfection activity | |
WO2012091523A3 (en) | Carrier for negatively charged drugs comprising a cationic lipid and a preparation method thereof | |
Sun et al. | Enhancing the therapeutic delivery of oligonucleotides by chemical modification and nanoparticle encapsulation | |
Moraes et al. | miRNA delivery by nanosystems: state of the art and perspectives | |
MY151268A (en) | Novel thermosensitive liposomes containing therapeutic agents | |
Munoz-Ubeda et al. | Effect of lipid composition on the structure and theoretical phase diagrams of DC-Chol/DOPE-DNA lipoplexes | |
Campani et al. | Lipid nanovectors to deliver RNA oligonucleotides in cancer | |
EP4043040A8 (en) | Small liposomes for delivery of immunogen-encoding rna | |
WO2012122313A3 (en) | Targeted nanocarrier systems for delivery of actives across biological membranes | |
Sen et al. | Design, syntheses, and transfection biology of novel non-cholesterol-based guanidinylated cationic lipids | |
Gaucheron et al. | Synthesis and properties of novel tetraalkyl cationic lipids | |
Nantz et al. | The benefit of hydrophobic domain asymmetry on the efficacy of transfection as measured by in vivo imaging |